2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

Olaparib Efficacy in Recurrent Ovarian Cancer: Is There OS Improvement With Maintenance Olaparib in Platinum-Sensitive BRCA+ Patients?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Oliver Dorigo
By 2020 ASCO Virtual Direct™ Highlights FEATURING Oliver Dorigo
35 views
February 2, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
GYN
07:34
2020 ASCO Virtual Direct™ Highlights

Olaparib Efficacy in Recurrent Ovarian Cancer: Is There OS Improveme…

Feat. O. Dorigo
09:04
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Recurrent Ovarian Cancer: Does Secondary Cytored…

Feat. O. Dorigo
04:17
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on GTT Resistant to Monochemotherapy: Should We Con…

Feat. O. Dorigo
07:21
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Post-Operative Adjuvant Therapy in Stage IB1 - I…

Feat. O. Dorigo
06:49
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Recurrent Ovarian Cancer: Does the Addition of M…

Feat. O. Dorigo